Colchicine did not significantly reduce major adverse cardiovascular events compared to placebo in patients with recent myocardial infarction (RR 0.83, 95% CI 0.66–1.04).
Does colchicine reduce major adverse cardiovascular events in patients with recent myocardial infarction?
In patients with recent myocardial infarction, the addition of colchicine to standard therapy does not significantly reduce major adverse cardiovascular events over a 1- to 3-year follow-up.
Absolute Event Rate: 0% vs 0%
Background The role of colchicine, an anti‐inflammatory agent, in improving cardiovascular outcomes in patients with recent myocardial infarction remains unclear. We sought to evaluate the efficacy and safety of colchicine compared with placebo in patients with recent myocardial infarction (within 1 month of symptom onset) at a follow‐up of at least 1 year. Methods We systematically searched MEDLINE, Embase, and the Cochrane Library until January 2025 for randomized controlled trials comparing colchicine to placebo in recent myocardial infarction. The primary outcome was major adverse cardiovascular events (MACE; as defined by the included studies) at maximum follow‐up. Secondary outcomes included individual MACE components and safety (serious adverse events AEs, any AEs, and gastrointestinal AEs). Count data were pooled using random‐effects models with inverse variance weighting to estimate risk ratios (RRs) and 95% CIs. Results A total of 5 randomized controlled trials were included with 6620 patients randomized to colchicine and 6625 to placebo. Most participants (79%) were male, with mean ages ranging from 59 to 61 years. Follow‐up durations ranged from 1 to 3 years. At maximum follow‐up, there was no statistically significant difference in MACE between colchicine and placebo (8.2% versus 9.3%; RR, 0.83 95% CI, 0.66–1.04). Analyses of individual MACE components were also inconclusive. Randomization to colchicine did not increase the overall incidence of AEs or serious AEs compared with placebo. Conclusions In patients with recent myocardial infarction, the available evidence assessing the effect of colchicine, in addition to standard therapy, on MACE remains inconclusive over a median follow‐up duration of 1 year.
Moiz et al. (Thu,) reported a other. Colchicine did not significantly reduce major adverse cardiovascular events compared to placebo in patients with recent myocardial infarction (RR 0.83, 95% CI 0.66–1.04).